Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy.

Meoni G, Lorini S, Monti M, Madia F, Corti G, Luchinat C, Zignego AL, Tenori L, Gragnani L.

Sci Rep. 2019 Mar 11;9(1):4128. doi: 10.1038/s41598-019-40028-4.

2.

Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification.

Wolahan SM, Hirt D, Glenn TC.

In: Kobeissy FH, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 25.

3.

Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.

Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.

J Viral Hepat. 2017 Dec;24(12):1098-1106. doi: 10.1111/jvh.12737. Epub 2017 Jul 29.

PMID:
28632923
4.

Coinfection of Schistosoma Species with Hepatitis B or Hepatitis C Viruses.

Abruzzi A, Fried B, Alikhan SB.

Adv Parasitol. 2016;91:111-231. doi: 10.1016/bs.apar.2015.12.003. Epub 2016 Feb 5. Review.

PMID:
27015949
5.

Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.

Khattab E, Chemin I, Vuillermoz I, Vieux C, Mrani S, Guillaud O, Trepo C, Zoulim F.

J Clin Virol. 2005 Jun;33(2):150-7. Epub 2004 Dec 18.

PMID:
15911431
6.

Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.

Comarmond C, Garrido M, Pol S, Desbois AC, Costopoulos M, Le Garff-Tavernier M, Si Ahmed SN, Alric L, Fontaine H, Bellier B, Maciejewski A, Rosenzwajg M, Klatzmann D, Musset L, Poynard T, Cacoub P, Saadoun D.

Gastroenterology. 2017 Jun;152(8):2052-2062.e2. doi: 10.1053/j.gastro.2017.02.037. Epub 2017 Mar 6.

PMID:
28274850
7.

Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.

Fabbri G, Mastrorosa I, Vergori A, Mazzotta V, Pinnetti C, Grisetti S, Zaccarelli M, Ammassari A, Antinori A.

BMC Infect Dis. 2017 Mar 1;17(1):182. doi: 10.1186/s12879-017-2287-y. Review.

8.

Hot News: Hepatitis B Gene Therapy Coming to Age.

Soriano V.

AIDS Rev. 2018 Apr-Jun;20(2):125-127. Review.

PMID:
29938706
9.

Differential metabonomic profiles of primary hepatocellular carcinoma tumors from alcoholic liver disease, HBV-infected, and HCV-infected cirrhotic patients.

Cao D, Cai C, Ye M, Gong J, Wang M, Li J, Gong J.

Oncotarget. 2017 Jun 7;8(32):53313-53325. doi: 10.18632/oncotarget.18397. eCollection 2017 Aug 8.

10.

Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs.

Bakacs T, Safadi R, Kovesdi I.

Hepatol Med Policy. 2018 Jan 5;3:2. doi: 10.1186/s41124-017-0028-x. eCollection 2018.

11.

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.

Mascia C, Vita S, ZuccalĂ  P, Marocco R, Tieghi T, Savinelli S, Rossi R, Iannetta M, Pozzetto I, Furlan C, Mengoni F, Mastroianni CM, Vullo V, Lichtner M.

PLoS One. 2017 Jun 21;12(6):e0179400. doi: 10.1371/journal.pone.0179400. eCollection 2017.

12.

T-cell therapy for chronic viral hepatitis.

Bertoletti A, Tan AT, Koh S.

Cytotherapy. 2017 Nov;19(11):1317-1324. doi: 10.1016/j.jcyt.2017.07.011. Epub 2017 Aug 25. Review.

PMID:
28847469
13.

The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy.

Shariff MIF, Kim JU, Ladep NG, Gomaa AI, Crossey MME, Okeke E, Banwat E, Waked I, Cox IJ, Williams R, Holmes E, Taylor-Robinson SD.

J Clin Exp Hepatol. 2017 Jun;7(2):83-92. doi: 10.1016/j.jceh.2017.03.007. Epub 2017 Mar 15.

14.

Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection.

Takayama H, Sato T, Ikeda F, Fujiki S.

Hepatol Res. 2016 Mar;46(5):489-91. doi: 10.1111/hepr.12578. Epub 2015 Sep 30.

PMID:
26297529
15.

Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

Chien RN.

Hepatol Int. 2008 Sep;2(3):296-303. doi: 10.1007/s12072-008-9066-1. Epub 2008 Apr 10.

16.

Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.

Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Yu ML.

Antivir Ther. 2005;10(1):125-33.

PMID:
15751770
17.

Treatment of chronic HCV genotype 1 coinfection.

Boesecke C, Rockstroh JK.

Curr HIV/AIDS Rep. 2015 Sep;12(3):326-35. doi: 10.1007/s11904-015-0278-4. Review.

PMID:
26228050
18.

NIH Consensus Statement on Management of Hepatitis C: 2002.

[No authors listed]

NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. Review.

19.

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

Gallay PA, Chatterji U, Bobardt MD, Long Z, Zhang S, Su Z.

PLoS One. 2016 Apr 22;11(4):e0152036. doi: 10.1371/journal.pone.0152036. eCollection 2016.

20.

Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.

Chen DS.

Princess Takamatsu Symp. 1995;25:27-32. Review.

PMID:
8875606

Supplemental Content

Support Center